Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 271

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 271
---
DiamiR does not expect CogniMIR
to be commercially available with reimbursement in place before fiscal 2027, if at all. DiamiR will need to raise substantial additional
capital to complete the development and commercialization of CogniMIR. Because successful development of CogniMIR
is uncertain, DiamiR is unable to estimate the actual funds required to complete research and development and commercialize CogniMIR.
DiamiR also will need to raise substantial additional capital to complete the development and commercialization of other products currently
in development.

Going Concern

DiamiR has a limited operating
history and incurred net losses of $743,235 and $614,405 for the years ended May 31, 2025 and 2024, respectively, and $283,700
in the three months ended August 31, 2025. DiamiR used net cash of $313,440 in the year ended May 31, 2025 and $171,585 in the three
months ended August 31, 2025 for operating activities. The accompanying consolidated financial statements have been prepared assuming
DiamiR will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities
in the normal course of business. These conditions raise substantial doubt about DiamiR’s ability to continue as a going concern
within twelve months after the date of the consolidated financial statements.

Since the inception of DiamiR
in December 2009, the operations of DiamiR has been funded primarily through grant funding, primarily received through the U.S. Department
of Treasury and the National Institutes of Health (“NIH”), as well as capital contributions of the founders of DiamiR. Management
believes this capital is insufficient to fund DiamiR’s operations for the next twelve months. Management does not anticipate
that DiamiR’s existing working capital alone will be sufficient to fund its operations through the successful development and commercialization
of products. As a result, DiamiR will need to raise additional capital to fund its operations and continue to conduct activities to support
its product development and commercialization activities. Management may raise additional funds by way of a public or private offering
or may be awarded additional grants.

Management cannot be certain
that additional funding will be available on acceptable terms, or at all. To the extent that DiamiR raises additional funds by issuing
equity securities, DiamiR’s shareholders may experience